Feb 3 (Reuters) - Pfizer Inc PFE.N:
PFIZER’S BRAFTOVI® COMBINATION REGIMEN SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PHASE 3 BREAKWATER TRIAL
PFIZER INC - BRAFTOVI COMBINATION REGIMEN IMPROVES SURVIVAL IN PHASE 3 TRIAL
PFIZER INC - BRAFTOVI COMBO SHOWS SIGNIFICANT IMPROVEMENT IN SURVIVAL FOR MCRC PATIENTS
PFIZER INC - TRIAL SHOWS SIGNIFICANT IMPROVEMENT IN PFS COMPARED TO CHEMOTHERAPY
PFIZER INC - BRAFTOVI COMBO SHOWS SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL
Source text: ID:nBw8fG0PXa
Further company coverage: PFE.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.